Asterias up 9% premarket on updated data on AST-OPC1
- BySeeking Alpha
- •
Asterias Biotherapeutics, Inc. is a biotechnology company that engages in the development and commercialization of therapies in the fields of cell therapy and regenerative medicine. It offers pluripotent stem cell and cancer immunotherapy platforms to develop therapeutics addressing significant unmet medical needs in neurology and oncology. It also develops AST-VAC1, an autologous product candidate for the treatment of acute myelogenous leukemia, and AST-VAC2, an allogeneic cancer vaccine candidate designed to stimulate patient immune responses; and through pluripotent it has developed AST-OPC1, which is for the treatment of spinal cord injury, multiple sclerosis, and stroke. Asterias Biotherapeutics, Inc. formerly known as BioTime Acquisition Corporation changed its name to Asterias Biotherapeutics, Inc. in March 2013. The company was incorporated in 2012 and is based in Fremont, California. As of March 8, 2019, Asterias Biotherapeutics, Inc. operates as a subsidiary of Lineage Cell Therapeutics, Inc.